Showing 6241-6250 of 7758 results for "".
- Taylor Harris Named New CEO at Cuterahttps://practicaldermatology.com/news/taylor-harris-named-new-ceo-at-cutera/2461892/Taylor Harris has been appointed Chief Executive Officer for Cutera, Inc., effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as memb
- Study Cites Surge in Google Searches for Skin of Color Sunscreenshttps://practicaldermatology.com/news/study-cites-surge-in-google-searches-for-skin-of-color-sunscreens/2461891/Growing numbers of people are searching for sunscreen for dark skin and sunscreen for black skin on Google, a new study shows. The estimated annual relative search volume (RSV) for "sunscreen for dark skin" ranged from 0 to 28, with the peak being reached in 2020.&nb
- Low Vitamin D Status Linked to PsO Severityhttps://practicaldermatology.com/news/low-vitamin-d-status-linked-to-pso-severity-2/2461887/Vitamin D levels may play a role in psoriasis severity, according to one of the largest studies to date. The analysis, which included almost 500 psoriasis cases from the National Health and Nutrition Examination Survey (NHANES), showed a linear relationship between increasing psoriasis
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bim
- EULAR Seeks to Classify Risk of PsA in PsO Patientshttps://practicaldermatology.com/news/eular-seeks-to-classify-risk-of-psa-in-pso-patients/2461867/New EULAR points-to-consider characterize the transition from skin to joint involvement in psoriatic disease. Overall, five overarching principles and 10 points-to-consider were formulated by a multidisciplinary task force of 30 members from 13 European countries. The principles ac
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Study: DermaSensor Correctly Identifies 96.2% of Melanomas in Senior Citizenshttps://practicaldermatology.com/news/study-dermasensor-correctly-identifies-962-of-melanomas-in-senior-citizens/2461863/DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting. The sensitivity of the DermaSensor device for melanoma
- Study: Men With Skin of Color Are More Likely to Die From Melanomahttps://practicaldermatology.com/news/study-men-with-skin-of-color-are-more-likely-to-doe-from-melanoma/2461853/Men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma, a new study in the Journal of the American Academy of Dermatology shows. "We know that men may be less likely to seek medical care than w
- Fecal Transplants Show Promise in Improving Response to Immunotherapy in Melanoma Patientshttps://practicaldermatology.com/news/fecal-transplants-show-promise-in-improving-response-to-immunotherapy-in-melanoma-patients/2461849/Fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma, according to research in Nature Medicine. Preliminar
- WCD News: Tildrakizumab Improves Wellbeing of PsO Patientshttps://practicaldermatology.com/news/wcd-news-tildrakizumab-improves-wellbeing-of-pso-patients/2461848/Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis, according to research reported by Almirall, S.A. (ALM) at poster at the 25th World Congress of Dermatology in Singapore. Patients taking tild